Selegiline and Reward Processing

• Status: Unknown status
• Trial end date: 2020-09-10
• Target enrollment: 0
• Participant gender: All

Summary

There has been growing interest in the relationship between reward processing and clinical symptoms of depression such as anhedonia (loss of interest and response to pleasurable activities).

The aim of the study is to investigate the acute effects of a single dose of selegiline (an irreversible monoamine oxidase B inhibitor) on reward and emotional processing in healthy volunteers.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Oxford
• Treatments: Selegiline

Criteria

Inclusion Criteria:

• 18-40 years of age

• Able to give informed consent for study participation

• Sufficient fluency in English to understand and complete the neuropsychological tasks

Exclusion Criteria:

• Current usage of other regular medication (including the contraceptive pill, the Depo-Provera injection or the progesterone implant, and hormone replacement therapy)

• Any past or current Axis 1 DSM-IV psychiatric disorder

• Significant medical condition

• Pulse < 60 beats per minute at baseline screening

• Current or past gastro-intestinal disorder or irritable bowel syndrome

• Current pregnancy or breastfeeding

• Known lactate deficiency or any other problem absorbing lactose, galactose or glucose

• Current or past history of drug or alcohol dependency

• Participation in a psychological or medical study involving the use of medication within the last 3 months

• Previous participation in a study using the same, or similar, emotional processing tasks

• Smoker > 5 cigarettes per day

• Typically drinks > 6 caffeinated drinks per day